GSK : Analysis & Opinions

  1. Hedge Your European Exposure With This Savvy ETF

    February 9, 2015
    The European Central Bank's (ECB) recent announcement of a huge bond-buying program has made investors understandably giddy. ...
  2. Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst ...

    January 28, 2015
    Novartis' core earnings per share came in at $1.21, up from $1.18 in the year-ago period and beat the Zacks Consensus Estimate ...
  3. Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst ...

    January 26, 2015
    Pfizer's (PFE) Prevenar 13 is a step closer to EU approval with the CHMP giving a favorable opinion for the prevention of ...
  4. Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? ...

    January 23, 2015
    Switzerland-based Novartis AG (NVS), one of the leading players in the healthcare solutions, will be reporting its fourth-quarter ...
  5. How To Profit From These 3 Overvalued Sectors

    January 22, 2015
    Flea markets crack me up. Most of the vendors seem like they cleaned the junk from their garage and assigned an arbitrary, ...
  6. GlaxoSmithKline, plc (GSK): New Analyst Report from Zacks Equity ...

    January 20, 2015
    Glaxo's third quarter 2014 earnings were up 5% (CER) to $0.93 per ADS, above the Zacks Consensus Estimate of $0.79. Revenues ...
  7. OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst ...

    January 16, 2015
    OncoMed Pharmaceuticals, Inc. (OMED) has enrolled the first biomarker-selected patient in the expansion stage of a phase ...
  8. Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst ...

    January 15, 2015
    Isis Pharmaceuticals (ISIS) earned a milestone payment of $7 million from partner Biogen for the advancement of the ongoing ...
  9. Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst ...

    January 15, 2015
    Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
  10. J&J Starts Ebola Vaccine Study, Updates Production Goal - Analyst ...

    January 7, 2015
    Johnson & Johnson (JNJ) commenced a phase I study on a preventive Ebola vaccine to evaluate the safety and tolerability ...
  11. Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly ...

    January 2, 2015
    Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company ...
  12. RedHill's Bekinda Accepted for Review in the EU, Shares Up - ...

    January 2, 2015
    Shares of RedHill Biopharma Ltd. (RDHL) surged after the company announced that the UK Medicines and Healthcare Products ...
  13. NewLink and Merck Get a $30M Contract for Ebola Candidate - ...

    December 29, 2014
    NewLink Genetics and Merck announced that the BARDA has awarded a $30 million contract for their Ebola vaccine candidate, ...
  14. Novartis' Alcon's Travatan Obtains Label Expansion in the EU ...

    December 26, 2014
    Novartis AG (NVS) recently announced that its ophthalmology arm Alcon was granted a label expansion by the European Commission ...
  15. BioCryst Rises on Positive Ebola Candidate Results - Analyst ...

    December 26, 2014
    Shares of BioCryst Pharmaceuticals (BCRX) rallied 6.9% after the announcement of results from a study on its Ebola virus ...
  16. Agenus Jumps on Positive Data from Shingles Candidate - Analyst ...

    December 19, 2014
    Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
  17. Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog

    December 16, 2014
    Roche's (RHHBY) subsidiary Genentech and Exelixis announced the submission of NDA for cobimetinib/Zelboraf combination for ...
  18. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  19. The Best- and Worst-Performing Healthcare Stocks

    November 3, 2014
    Here are the best- and worst-performing stocks YTD in the healthcare sector with at least $2B in market cap and over 1 million ...
  20. Why There's Far More To Pfizer Than Viagra

    July 30, 2014
    Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little ...
  21. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  22. Learn How To Invest Defensively From This Hedge Fund Pro

    May 21, 2014
    With the Dow Jones Industrial Average and the S&P 500 hovering near all-time highs and plenty of investors shifting to a ...
  23. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  24. Sectors and Stocks to Watch This Week

    March 3, 2014
    Very strong coming into this week, these are sectors and stocks to keep an eye on.
  25. European Stocks Are Ripe For The Picking

    February 26, 2014
    Things continue to get better for Europe. After going through some pretty nasty side-effects in the aftermath of the Great ...
  26. The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  27. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  28. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  29. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  30. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  31. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  32. Glaxo Initiates Phase III Study - Analyst Blog

    July 8, 2013
    GlaxoSmithKline has initiated a phase III study on a subcutaneous formulation of Arzerra
  33. Dr. Reddy's Launches Generic Lamictal XR - Analyst Blog

    July 1, 2013
    Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Glaxo's Lamictal XR (lamotrigine) extended-release ...
  34. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  35. Glaxo Gets Offer for Thrombosis Drugs - Analyst Blog

    June 19, 2013
    GlaxoSmithKline announced that Aspen Pharmacare Holdings Limited has offered to buy Glaxo's thrombosis brands
  36. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  37. Elan Continues To Make Baffling Strategic Decision

    May 21, 2013
    Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
  38. Another Negative Fish Oil Study Adds To Amarin's Marketing Challenges

    May 9, 2013
    More questions about the real efficacy of fish oil is bad news for Amarin.
  39. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  40. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  41. Gains of 27%, 56%, and even 183%... What's Next?

    January 2, 2013
    It's every investor's dream. And this one came true... For lucky shareholders in this formerly tiny maker of automated medicine ...
  42. A Triple Play Of Biotech Disappointments Last Week

    December 28, 2012
    Investors got a triple-dose of bad biotech news this week.
  43. Glaxo Invests in Nigeria - Analyst Blog

    November 28, 2012
    GlaxoSmithKline (GSK) recently announced that it has reached an agreement with GlaxoSmithKline Consumer Nigeria plc regarding ...
  44. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  45. LIFE Continues Acquisition Spree - Analyst Blog

    October 9, 2012
    Life Technologies (LIFE) is on an acquisition bandwagon, targeted towards building its diagnostics franchise. The company ...
  46. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  47. Roche Oncology Candidate Progresses - Analyst Blog

    October 2, 2012
    Roche Holdings Ltd. (RHHBY) recently announced additional results from its phase III EMILIA study, which was conducted with ...
  48. GlaxoSmithKline, plc (GSK) - Bear of the Day

    August 14, 2012
    GlaxoSmithKline, plc's (GSK) second quarter earnings of $0.79 per ADS were below the Zacks Consensus Estimate of $0.84. Earnings ...
  49. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  50. UK's Global Footprint Stocks

    June 27, 2012
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  51. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  52. Truly a World-Class Fund

    April 26, 2012
    There’s no one place for growth any longer, so it pays to diversify across world markets and few funds do it better than ...
  53. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  54. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  55. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  56. Despite Inflation Woes India Outshines In Asia

    September 23, 2011
    Despite its inflationary pressures, India's strength and investment potential continues to grow.
  57. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  58. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  59. Buffett's Profitable Positions

    July 13, 2011
    See 5 stocks that have been profitable for Warren Buffett.
  60. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  61. Dividends To Avoid

    May 4, 2011
    A company that offers dividends isn't always a safe long-term bet. Find out which dividend-issuing companies you should avoid.
  62. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  63. U.K. A Value Bet Amid Euro Debt Crisis

    January 20, 2011
    The ongoing financial crisis in the European Union has made the United Kingdom a promising prospect for value investors. ...
  64. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  65. Human Genome Takes A Big Step Forward

    November 17, 2010
    HGSI's prospects get a big boost from a panel approval.
  66. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact ...
  67. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  68. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  69. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  70. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  71. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  72. Fighting The Unstable European Union

    March 3, 2010
    Protection is the name of the game, and these options can help shield you from a volatile European Union.
  73. Four High-Flying Pharmaceutical Companies

    October 28, 2009
    A look at some of the best-performing stocks year to date - up anywhere from 400% to 2000%.
  74. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  75. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  76. Dividend Darlings Or Dividend Disappointments?

    March 26, 2009
    Even with declining sales, Whirlpool has the stock prices and dividend yields that make it a company of interest.
  77. Will Emergent BioSolutions Finally Retreat?

    January 12, 2009
    Having lost positive earnings and revenue momentum, EBS is looking less healthy in 2009.
  78. Ride The Ups And Downs Of Drug Approval

    October 16, 2008
    The FDA's complex drug approval process provides plenty of volatility for short-term traders to feast upon.
  79. Abbott Labs Finally Turns Potential Into Profit

    April 17, 2008
    Solid numbers for the last two quarters could change Abbott Labs's reputation as an overvalued stock.
  80. You Gotta Know When To Bail

    February 22, 2007
    When your stock's prospects take a turn for the worse, bailing out can be the best possible option.
  81. Winners and Losers - September 4th - 8th (SYX, BNP, EFX, ADLR, ...

    September 8, 2006
    A look at the winners and losers for the week of September 4th.
  82. Pfizer, Pass the Rolaids

    June 12, 2006
    $15 billion for its consumer products unit won’t cure Pfizer’s ailing stock.
  83. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Trading Center